TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04490187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Learning
Description: Over three consecutive days, each child will perform five blocks of Purdue Pegboard Test: one block before, three blocks during, and one block after tDCS. Each block consists of three repetitions of Purdue Pegboard Test with the right hand. The children have to place pins into a pegboard as fast as they can in 30 seconds. It will take up to 10 minutes of brain stimulation time.~After the Purdue Pegboard Test, each child will receive cognitive-based intervention for printing skills for 20 minutes while receiving tDCS. Printing Like a Pro! (Montgomery 2017) -a cognitive approach to teaching printing to primary school-age children-will be used to teach letters which each child has the most difficulty printing legibly as identified on a formal assessment of handwriting-ETCH (manuscript) (Amundson 1995).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motor Learning
Description: Over three consecutive days, each child will perform five blocks of Purdue Pegboard Test: one block before, three blocks during, and one block after tDCS. Each block consists of three repetitions of Purdue Pegboard Test with the right hand. The children have to place pins into a pegboard as fast as they can in 30 seconds. It will take up to 10 minutes of brain stimulation time.~After the Purdue Pegboard Test, each child will receive cognitive-based intervention for printing skills for 20 minutes while receiving tDCS. Printing Like a Pro! (Montgomery 2017) -a cognitive approach to teaching printing to primary school-age children-will be used to teach letters which each child has the most difficulty printing legibly as identified on a formal assessment of handwriting-ETCH (manuscript) (Amundson 1995).
Study: NCT02375178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0.12% chlorhexidine solution. Samples of saliva will be collected immediately before the mouth wash and after 30, 60 and 180 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide
Description: The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0,07% solution Polyhexamethylene biguanide. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile saline solution
Description: The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of a sterile saline solution. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile saline solution
Description: The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of a sterile saline solution. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile saline solution
Description: The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of a sterile saline solution. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
Study: NCT01580969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered in accordance with the FDA-approved dose for gliomas, 10mg/kg IV every 2 weeks. Bevacizumab will be continued every two weeks as long as tolerated. One cycle of bevacizumab will be 28 days, with treatments on day1 and day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered in accordance with the FDA-approved dose for gliomas, 10mg/kg IV every 2 weeks. Bevacizumab will be continued every two weeks as long as tolerated. One cycle of bevacizumab will be 28 days, with treatments on day1 and day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered in accordance with the FDA-approved dose for gliomas, 10mg/kg IV every 2 weeks. Bevacizumab will be continued every two weeks as long as tolerated. One cycle of bevacizumab will be 28 days, with treatments on day1 and day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline will be given by mouth twice a day at the assigned dose level. Minocycline will be started on the day prior to radiation and continued until progression or intolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline will be given by mouth twice a day at the assigned dose level. Minocycline will be started on the day prior to radiation and continued until progression or intolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline will be given by mouth twice a day at the assigned dose level. Minocycline will be started on the day prior to radiation and continued until progression or intolerance.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation planning will be individualized by the radiation oncologist based on the location of the current radiation field relative to prior radiation doses. The length and fractionation will be determined individually by the radiation oncologist.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation planning will be individualized by the radiation oncologist based on the location of the current radiation field relative to prior radiation doses. The length and fractionation will be determined individually by the radiation oncologist.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation planning will be individualized by the radiation oncologist based on the location of the current radiation field relative to prior radiation doses. The length and fractionation will be determined individually by the radiation oncologist.
Study: NCT01771120

Intervention type: OTHER
Intervention: Diagnostic tests, medical interview and questionnaires
Description: All patients will perform these interventions.

Intervention type: OTHER
Intervention: Diagnostic tests, medical interview and questionnaires
Description: All patients will perform these interventions.

Intervention type: OTHER
Intervention: Diagnostic tests, medical interview and questionnaires
Description: All patients will perform these interventions.

Intervention type: OTHER
Intervention: Diagnostic tests, medical interview and questionnaires
Description: All patients will perform these interventions.
Study: NCT02731794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: left ventricular assist
Description: In left ventricular assist group, 100 IU/kg heparin was given to activated clotting time (ACT) greater than 180 seconds. A 22 French arterial cannula (Maquet, Irrlingen, Germany) was introduced into the ascending aorta, and a 26 French cannula (Eurosets, Medolla, Italy) into the left atrium and advanced into the left ventricle. The two cannulas are directly connected through a short, heparin-coated circuit to a centrifuge pump (Maquet, Getinge Group, Germany). A flow of 1.0 to 4.0 L/min/m2 is obtained and mean blood pressure was maintained 55-75 mm Hg. Note: Both LVA group and BiVA group have the operative protocols itself,includes different prime fluid and cannula pathway. The investigators think it is inapplicable to assign the different operative protocols to the Treatment Arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular assist
Description: In biventricular assist group, the patients were routinely heparinized with a dose of 300 IU/kg heparin to ACT greater than 480 seconds. Cardiopulmonary bypass with a centrifuge pump (Maquet, Getinge Group, Germany) was established by 22 French aortic cannulation and 34 French two-stage venous cannula through the right atrial appendage. The extracorporeal circuit was primed with 2000 mL of lactated Ringer's solution, albumin, 25% mannitol and 5% NaHCO3. The flow was 1.0 to 4.0 L/min/m2 and mean blood pressure was maintained 55-75 mm Hg.
Study: NCT02172274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BI 10773 - oral solution
Study: NCT04461717

Intervention type: DEVICE
Intervention: MicroNet covered stent implantation in the increased risk arterial lesions beyond the carotid bifurcation
Description: Implantation of the MicroNet covered stent in the increased risk arterial lesions beyond the carotid bifurcation as per Vascular Team recommendation
Study: NCT04317287

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardio formulation
Description: Tomato-based formulation with dietary supplement softgels

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo softgels
Study: NCT03523429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blinatumomab
Description: Blinatumomab is a bispecific monoclonal antibody designed to bind specifically to CD19, expressed on the surface of B-cells, and to CD3, expressed on the surface of T-cells. It activates endogenous T-cells by connecting the CD3 on the T-cell receptor complex (TCR) with the CD19 on the B-cells. The anti-tumour activity of blinatumomab does not depend on whether the T-cells carry a specific TCR or peptide antigens present in cancer cells, but it is polyclonal and independent of HLA on the target cells
Study: NCT02761161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mianserin
Description: mianserin is add-on treatment to treatment as usual. Max dose 30 mg day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mianserin
Description: mianserin is add-on treatment to treatment as usual. Max dose 30 mg day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imagery Rehearsal Therapy
Description: IRT is add-on treatment to treatment as usual.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imagery Rehearsal Therapy
Description: IRT is add-on treatment to treatment as usual.
Study: NCT00666393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl iontophoretic transdermal system (40mcg) No placebo
Description: 40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl iontophoretic transdermal system (40mcg)
Description: 40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
Study: NCT04680754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: head-neck stretching exercises
Description: Neck stretching exercises which include basic movements of the neck are simple and effective exercises. Stretching exercises provide neuromuscular coordination and flexibility in patients by reducing pain and muscle weakness (Nakamura, Kodama, and Mukaino 2014). For this reason, neck stretching exercises should be performed in early postoperative period and a nurse should teach the patient the head-neck stretching exercises and ensure the patient's comfort after thyroidectomy.
Study: NCT06341348

Intervention type: OTHER
Group type: OTHER
Intervention: Case management
Description: Case Management (CM) is multi-component interventions, that comprised the provision of health education and professional advice, referring the client to another health care team, discussing a daily life plan, making reservations, and follow-up by telephone. All interventions were delivered by a nursing case manager who had over 5 years of nursing experience and received more than 20 hours of CM training.
Study: NCT01844947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: Vinflunine (Javlor®, Pierre Fabre Pharma): 320 mg/m2 I.V., day 1, repeated every 21 days for patients with PS 0, adequate renal (creatinine clearance \>60 ml/min) and hepatic function (as described in the inclusion criteria). PLEASE NOTE THAT THE 320 mg/m2 ARM IS CLOSED FOR RECRUITMENT.~For patients with PS 1, or age 75 to 80 years, or exposed to radiation of the lower pelvis region, or with impaired renal function (creatinine clearance 40-60 ml/min) but adequate hepatic function (as described in the inclusion criteria), the dose of vinflunine is 280 mg/m2 I.V. day 1, repeated every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib (Nexavar®, Bayer HealthCare) daily dosage from day 2 through day 21 (repeated every 21 days):~Step 1: 400 mg P.O. (i.e. one (1) tablet 200 mg morning and evening, 1+0+1) Step 2: 600 P.O. (i.e. one (1) tablet 200 mg morning and two tablets evening, 1+0+2) Step 3: 800 mg P.O. (i.e. two (2) tablets 200 mg morning and evening, 2+0+2) Doses of sorafenib higher than 400 mg P.O. b.i.d. are not allowed.
Study: NCT02569203

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: standard enteral nutrition
Description: standard enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
Description: high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-protein enteral nutrition of immune modulating nutrients without β-glucan
Description: high-protein enteral nutrition of immune modulating nutrients without β-glucan
Study: NCT02707237

Intervention type: OTHER
Group type: OTHER
Intervention: Verbal counseling
Description: Verbal counseling done by physician

Intervention type: OTHER
Group type: OTHER
Intervention: Verbal, pictorial, written counseling
Description: verbal counseling in addition to gestational age specific written information and pictures will be given to parents
Study: NCT02039453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl doses
Description: fentanyl doses 50μg (37.5kg to 62.5kg), 75μg (62.5kg to 87.5kg), 100μg (\>87.5kg), single use Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
Study: NCT00445042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the protocol, providing no dose limiting toxicity (Grade 3 or 4) is observed.
Study: NCT03488953

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Living donor liver transplantation with two-staged hepatectomy.
Description: Two-stage hepatectomy combined with transplantation of left-lateral lobe from a living donor.
Study: NCT02039453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pethidine dose
Description: pethidine dose 50mg, IV bolus (25mg if \< 50kg or \>70 years or significant co-morbidity), Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
Study: NCT01285609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Study: NCT03643848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep with Sound Cues
Description: Experimental manipulation to observe effects on memory for learned material.
Study: NCT01079741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein; Poly-ICLC; Montanide
Description: Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen (100µg) and Montanide (1.1mL) will be held constant.~Phase II: The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NY-ESO-1 protein; Poly-ICLC; Montanide
Description: Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen (100µg) and Montanide (1.1mL) will be held constant.~Phase II: The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B).
Study: NCT05021523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot ambient conditions exposures
Description: Participants rest or exercise for 40min to 1h daily in hot ambient conditions

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Immobilization
Description: Participants are wearing a walking boot (with crutches) for 2 weeks
Study: NCT03643848

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep with Sham Cues
Description: Sham manipulation
Study: NCT04169217

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation
Description: A combination of a one off workshop and mentored prehabilitation.~Covid Pandemic amendment: The workshop was originally a group based face to face patient workshop. This intervention is now (since the first national lockdown in March 2020) a virtual workshop using a the Bluejeans platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: A combination of a one off workshop and mentored prehabilitation.~Covid Pandemic amendment: The workshop was originally a group based face to face patient workshop. This intervention is now (since the first national lockdown in March 2020) a virtual workshop using a the Bluejeans platform.
Study: NCT05021523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immobilization
Description: Participants are wearing a walking boot (with crutches) for 2 weeks
Study: NCT04302441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: vinorelbine 25mg/m2 on day 1 and 8,every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle
Study: NCT01048580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine 50 mg orally once a day (Days 1-21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 orally twice per day (Days 1-14)
Study: NCT02957864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir alafenamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abacavir
Study: NCT01445067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-927711 (CGRP Antagonist)
Description: Capsule, Oral, 300 mg, Once, One day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-927711 (CGRP Antagonist)
Description: Capsule, Oral, 600 mg, Once, One day
Study: NCT02749240

Intervention type: OTHER
Group type: OTHER
Intervention: Youth Empowerment Seminar, YES!
Description: An 8-week innovative bio-psycho-social program.
Study: NCT04320797

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry analysis of urine samples
Description: Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry analysis of urine samples
Description: Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326
Study: NCT02043678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: 50 kiloBecquerel per kilogram (kBq/kg) (55 kBq/kg after implementation of NIST update) body weight, intravenous injection (IV-slow bolus), every 4 weeks for 6 cycles
Study: NCT03710499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit.
Study: NCT00887536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel 75 mg/m2 IV every 21 days for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel 75 mg/m2 IV every 21 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel 75 mg/m2 IV every 21 days for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: doxorubicin 50 mg/m2 IV every 21 days for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles \[filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.\]